HRP20150330T1 - Pripravci i postupci uporabe prostaniäśnog peptida za stanice otoäśiä†a i njegovih analoga - Google Patents
Pripravci i postupci uporabe prostaniäśnog peptida za stanice otoäśiä†a i njegovih analoga Download PDFInfo
- Publication number
- HRP20150330T1 HRP20150330T1 HRP20150330TT HRP20150330T HRP20150330T1 HR P20150330 T1 HRP20150330 T1 HR P20150330T1 HR P20150330T T HRP20150330T T HR P20150330TT HR P20150330 T HRP20150330 T HR P20150330T HR P20150330 T1 HRP20150330 T1 HR P20150330T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- peptide
- cells
- peptide according
- human
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 54
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 241000283690 Bos taurus Species 0.000 claims 5
- 241000699800 Cricetinae Species 0.000 claims 4
- 241000282577 Pan troglodytes Species 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 241001494479 Pecora Species 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101001096072 Homo sapiens Regenerating islet-derived protein 3-gamma Proteins 0.000 claims 2
- 108010035620 INGAP peptide Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 101100301514 Rattus norvegicus Reg3g gene Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 108700025316 aldesleukin Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 238000005457 optimization Methods 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 108010044644 pegfilgrastim Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 claims 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010002659 Anovulatory cycle Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 101000966379 Bos taurus Lithostathine Proteins 0.000 claims 1
- 101001028762 Bos taurus Phosphate carrier protein, mitochondrial Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 235000021318 Calcifediol Nutrition 0.000 claims 1
- 102000006303 Chaperonin 60 Human genes 0.000 claims 1
- 108010058432 Chaperonin 60 Proteins 0.000 claims 1
- 102100025892 Complement C1q tumor necrosis factor-related protein 1 Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101001021527 Homo sapiens Huntingtin-interacting protein 1 Proteins 0.000 claims 1
- 101000872458 Homo sapiens Huntingtin-interacting protein 1-related protein Proteins 0.000 claims 1
- 101000581802 Homo sapiens Lithostathine-1-alpha Proteins 0.000 claims 1
- 101000581803 Homo sapiens Lithostathine-1-beta Proteins 0.000 claims 1
- 101000581815 Homo sapiens Regenerating islet-derived protein 3-alpha Proteins 0.000 claims 1
- 101001096074 Homo sapiens Regenerating islet-derived protein 4 Proteins 0.000 claims 1
- 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 claims 1
- 102100035957 Huntingtin-interacting protein 1 Human genes 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 1
- 108010019598 Liraglutide Proteins 0.000 claims 1
- 108010014691 Lithostathine Proteins 0.000 claims 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 claims 1
- 101100160997 Mus musculus Rchy1 gene Proteins 0.000 claims 1
- 101100343530 Mus musculus Reg2 gene Proteins 0.000 claims 1
- 101100412400 Mus musculus Reg3a gene Proteins 0.000 claims 1
- 101100412402 Mus musculus Reg3b gene Proteins 0.000 claims 1
- 101100301513 Mus musculus Reg3g gene Proteins 0.000 claims 1
- 101100301519 Mus musculus Reg4 gene Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 229940122344 Peptidase inhibitor Drugs 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 108700012361 REG2 Proteins 0.000 claims 1
- 101150108637 REG2 gene Proteins 0.000 claims 1
- 108091058543 REG3 Proteins 0.000 claims 1
- 108700012368 REG3B Proteins 0.000 claims 1
- 241000700157 Rattus norvegicus Species 0.000 claims 1
- 101001035657 Rattus norvegicus 28 kDa heat- and acid-stable phosphoprotein Proteins 0.000 claims 1
- 101000976209 Rattus norvegicus Endoribonuclease ZC3H12A Proteins 0.000 claims 1
- 101100120298 Rattus norvegicus Flot1 gene Proteins 0.000 claims 1
- 101100412403 Rattus norvegicus Reg3b gene Proteins 0.000 claims 1
- 101150043784 Reg3b gene Proteins 0.000 claims 1
- 102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 claims 1
- 102100037886 Regenerating islet-derived protein 3-gamma Human genes 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 210000004504 adult stem cell Anatomy 0.000 claims 1
- 108010056243 alanylalanine Proteins 0.000 claims 1
- 229960005310 aldesleukin Drugs 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 229940030156 cell vaccine Drugs 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960004042 diazoxide Drugs 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 210000003890 endocrine cell Anatomy 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
- 229960002706 gusperimus Drugs 0.000 claims 1
- 102000045287 human REG1A Human genes 0.000 claims 1
- 102000045286 human REG1B Human genes 0.000 claims 1
- 102000045701 human REG3G Human genes 0.000 claims 1
- 102000053579 human REG4 Human genes 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000008004 immune attack Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 claims 1
- 229960002701 liraglutide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims 1
- 230000009707 neogenesis Effects 0.000 claims 1
- 229940071846 neulasta Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims 1
- 229960001373 pegfilgrastim Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 229960003611 pramlintide Drugs 0.000 claims 1
- 108010029667 pramlintide Proteins 0.000 claims 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 229940087463 proleukin Drugs 0.000 claims 1
- 229940099538 rapamune Drugs 0.000 claims 1
- UAOCLDQAQNNEAX-ABMICEGHSA-N remogliflozin etabonate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)OCC)O[C@H]1OC1=NN(C(C)C)C(C)=C1CC1=CC=C(OC(C)C)C=C1 UAOCLDQAQNNEAX-ABMICEGHSA-N 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229950010127 teplizumab Drugs 0.000 claims 1
- 229940107955 thymoglobulin Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4733—Acute pancreatitis-associated protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
Claims (10)
1. Prostanični peptid za stanice otočića izabran iz grupe koja obuhvaća HIP1 peptid (SEQ ID NO: 3), HIP2 peptid (SEQ ID NO: 4), HIP3 peptid (SEQ ID NO: 2), humani REG3A peptid (SEQ ID NO: 30), humani REG3G peptid (SEQ ID NO: 81), humani REG1A peptid (SEQ ID NO: 67), humani REG1B peptid (SEQ ID NO: 68), humani REG4 peptid (SEQ ID NO: 85), hrčkov INGAP peptid (SEQ ID NO: 27, 32, 39, ili 46), hrčkov REG2 peptid (SEQ ID NO: 72), hrčkov REG3G peptid (SEQ ID NO: 80), štakorov REG1 peptid (SEQ ID NO: 69), štakorov PAP/REG3B peptid (SEQ ID NO: 74), štakorov PAP3 peptid (SEQ ID NO: 75), štakorov REG3G peptid (SEQ ID NO: 79), mišji REG I peptid (SEQ ID NO: 70), mišji REG2 peptid (SEQ ID NO: 71), mišji REG3A peptid (SEQ ID NO: 33, 40, 47, ili 53), mišji REG3B peptid (SEQ ID NO: 77), mišji REG3G peptid (SEQ ID NO: 78), mišji REG3S peptid (SEQ ID NO: 82), mišji REG4 peptid (SEQ ID NO: 86), goveđi PTP peptid (SEQ ID NO: 83), REG3 peptid norveškog štakora (SEQ ID NO: 34, 41, 48, ili 54), peptid čimpanze prema SEQ ID No 31, peptid čimpanze prema SEQ ID NO: 38, peptid čimpanze prema SEQ ID NO: 45, peptid čimpanze prema SEQ ID NO: 52, peptid čimpanze prema SEQ ID NO: 60, goveđi peptid prema SEQ ID NO: 35, goveđi peptid prema SEQ ID NO: 42, goveđi peptid prema SEQ ID NO: 49, goveđi peptid prema SEQ ID NO: 55, goveđi peptid prema SEQ ID NO: 88, pseći peptid prema SEQ ID NO: 36, pseći peptid prema SEQ ID NO: 43, pseći peptid prema SEQ ID NO: 50, pseći peptid prema SEQ ID NO: 56, ovčji peptid prema SEQ ID NO: 37, ovčji peptid prema SEQ ID NO: 44, ovčji peptid prema SEQ ID NO: 51, ovčji peptid prema SEQ ID NO: 57 gdje prostanični peptid za stanice otočića obuhvaća optimizacijsku modifikaciju i gdje je ta optimizacijska modifikacija C-terminalna amidna skupina i N-terminalna acetilna skupina.
2. Peptid prema zahtjevu 1, gdje taj peptid obuhvaća aminokiselinsku sekvencu SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO:7, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 24 ili SEQ ID NO: 25.
3. Farmaceutski pripravak koji sadrži farmaceutsku pomoćnu tvar i prostanični peptid za stanice otočića prema bilo kojem od zahtjeva 1 do 2 u terapijski učinkovitoj količini.
4. Farmaceutski pripravak prema zahtjevu 3, gdje je ta terapijski učinkovita količina od 0.5 do 5 mg/kg/dan.
5. Farmaceutski pripravak prema zahtjevu 3, gdje je terapijski učinkovita količina od 60 do oko 180 mg/dan.
6. Prostanični peptid za stanice otočića prema bilo kojem od zahtjeva 1 do 2 za uporabu u stimulaciji neogeneze otočića ili stimulaciji regeneracije stanica otočića gušterače.
7. Peptid prema bilo kojem od zahtjeva 1 do 2 za uporabu prema zahtjevu 6, gdje je taj peptid za primjenu u kombinaciji sa sredstvom za regeneraciju stanica otočića gušterače, po izboru izabranom između humanih prostaničnih peptida za stanice otočića, analoga humanih prostaničnih peptida za stanice otočića, amilina, pramlintida, eksendin-4, GIP, GLP-1, agonista GLP-1 receptora, GLP-1 analoga, hrčkovog INGAP peptid, liraglutida i inhibitora dipeptidil peptidaze.
8. Prostanični peptid za stanice otočića prema bilo kojem od zahtjeva 1 do 2 za uporabu u liječenju patologije povezane s poremećajem funkcije gušterače u subjekta.
9. Peptid prema bilo kojem od zahtjeva 1 do 2 za uporabu prema zahtjevu 8, gdje se patologija povezana s poremećajem funkcije gušterače izabire između dijabetesa tipa 1, novog dijabetesa tipa 1, dijabetesa tipa 2, latentnog autoimunog dijabetesa u odraslih, pre-dijabetesa, poremećaja glukoze natašte, poremećaja tolerancije na glukozu, sindroma otpornosti na inzulin, metaboličkog sindroma/dismetaboličkog sindroma, prekomjerne težine, pretilosti, hiperlipidemije, hipertrigliceridemije, poremećaja hranjenja, anovulatornih ciklusa i sindroma policističnih jajnika.
10. Peptid prema bilo kojem od zahtjeva 1 do 2 za uporabu prema zahtjevu 8, gdje je taj peptid za primjenu u kombinaciji sa sredstvom koje inhibira, blokira ili uništava autoimune stanice koje ciljaju endokrine stanice gušterače, po izboru se izabire između jednog ili više od sljedećih sredstava: anti CD-3 protutijela uključujući hOKT3γ1(Ala-Ala) (teplizumab); ChAglyCD3 koji cilja imuni odgovor i specifično blokira T-limfocite koji uzrokuju smrt beta stanica u dijabetesu tipa 1; citotoksični T-limfocitni antigen 4, CLTA-4 Ig (Abatacept); Sirolimus (Rapamicin) sam ili u kombinaciji s takrolimusom (FK506) ili IL-2 (rapamunom); Rapamun sam ili u kombinaciji s proleukinom (aldesleukin); protein 60 toplinskog šoka (Diapep277); cjepivo protiv dekarboksilaze 65 glutaminske kiseline (GAD65); lizofilin, IBC-VSO, cjepivo, interferon-alfa, CD4+CD25+ antigen-specifično regulatorno T stanično cjepivo; dijabetes-supresivno dendritično stanično cjepivo, GSK189075, diazoksid i statini uključujući atorvastatin korišten kao sredstvo za očuvanje funkcije beta stanica, mikofenolat mofetil sam ili u kombinaciji s daklizumabom; anti-CD20 sredstvo, Rituksimab; Campath-1H (Anti-CD52 protutijelo), lizofilin; poliklonski anti-T-limfocitni globulin (ATG/Timoglobulin), faktor stimulacije kolonije granulocita, Neulasta (Pegfilgrastim), Vitamin D, i 25 hidroksi i 1,25 hidroksi vitamin D nadomjestak; IBC-VSO cjepivo, koje je sintetički, metabolički inaktivni oblik inzulina napravljeno za sprečavanje uništenja beta stanica gušterače; interferon-alfa; cjepivo koje koristi CD4+CD25+ antigen- specifične regulatorne T stanice ili bilo koje sredstvo ili sredstva napravljena za supresiju imunog napada na beta stanice u Langerhansovim otočićima, Prochymal (Humane odrasle matične stanice), anti-inflamatorna Anakinra i antinflamatorno sredstvo, Deoksispergualin, anti-inflamatorno sredstvo koje blokira proizvodnju proinflamatornih citokina i inhibira T-stanice i B- stanice.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96901907P | 2007-08-30 | 2007-08-30 | |
US97952607P | 2007-10-12 | 2007-10-12 | |
US99196407P | 2007-12-03 | 2007-12-03 | |
US3147908P | 2008-02-26 | 2008-02-26 | |
EP08798997.6A EP2193142B1 (en) | 2007-08-30 | 2008-08-29 | Compositions and methods of using proislet peptides and analogs thereof |
PCT/US2008/074868 WO2009029847A1 (en) | 2007-08-30 | 2008-08-29 | Compositions and methods of using proislet peptides and analogs thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150330T1 true HRP20150330T1 (hr) | 2015-06-19 |
Family
ID=40084133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150330TT HRP20150330T1 (hr) | 2007-08-30 | 2015-03-23 | Pripravci i postupci uporabe prostaniäśnog peptida za stanice otoäśiä†a i njegovih analoga |
Country Status (26)
Country | Link |
---|---|
US (2) | US8816047B2 (hr) |
EP (3) | EP2559700A3 (hr) |
JP (2) | JP2010538017A (hr) |
KR (1) | KR20100080519A (hr) |
CN (1) | CN101896499B (hr) |
AU (1) | AU2008292913B2 (hr) |
BR (1) | BRPI0815308A2 (hr) |
CA (1) | CA2698100C (hr) |
CO (1) | CO6270235A2 (hr) |
CY (1) | CY1116169T1 (hr) |
DK (1) | DK2193142T3 (hr) |
EA (1) | EA201000399A1 (hr) |
ES (1) | ES2534434T3 (hr) |
HK (1) | HK1144823A1 (hr) |
HR (1) | HRP20150330T1 (hr) |
IL (2) | IL233024A (hr) |
MA (1) | MA31822B1 (hr) |
MX (2) | MX337147B (hr) |
MY (1) | MY165889A (hr) |
NZ (3) | NZ599756A (hr) |
PL (1) | PL2193142T3 (hr) |
PT (1) | PT2193142E (hr) |
SG (1) | SG185940A1 (hr) |
SI (1) | SI2193142T1 (hr) |
WO (1) | WO2009029847A1 (hr) |
ZA (1) | ZA201001798B (hr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
US8211430B2 (en) * | 2005-03-04 | 2012-07-03 | Curedm Group Holdings, Llc | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
EP1883417A2 (en) | 2005-05-25 | 2008-02-06 | Curedm Inc. | Peptides, derivatives and analogs thereof, and methods of using same |
KR20100080519A (ko) * | 2007-08-30 | 2010-07-08 | 큐어디엠 인코포레이티드 | 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법 |
US20130323293A1 (en) * | 2011-02-24 | 2013-12-05 | Takuya Umemoto | Glp-1 analogue composition for microneedle devices |
JP6416627B2 (ja) | 2012-01-09 | 2018-10-31 | セルピン ファーマ リミテッド ライアビリティ カンパニー | ペプチドおよびその使用法 |
RU2480234C1 (ru) * | 2012-03-01 | 2013-04-27 | Закрытое акционерное общество "Инновационный научно-производственный центр "Пептоген" | Способ профилактики и лечения нарушений углеводного и липидного обмена при метаболическом синдроме и энцефалопатии, применение тетрапептида и фармацевтическая композиция для профилактики и лечения таких нарушений |
CN106668852B (zh) * | 2012-04-13 | 2020-12-25 | 艾棣维欣(苏州)生物制药有限公司 | 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用 |
US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
CN104519900A (zh) | 2012-06-27 | 2015-04-15 | 欧尔本生物科技有限责任公司 | 用于治疗糖尿病的ctla4融合蛋白 |
AU2013323476A1 (en) * | 2012-09-27 | 2015-07-30 | Claresa LEVETAN | Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent |
EP2900691A4 (en) * | 2012-09-27 | 2016-04-20 | Claresa Levetan | GENERATION OF NEW CELLS BETA OF PANCREAS |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
GB201220901D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
AR094180A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Derivados de exendina-4 |
CN104650212A (zh) * | 2013-03-15 | 2015-05-27 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用 |
CN104045698B (zh) * | 2013-03-15 | 2019-04-16 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104592380A (zh) * | 2013-03-15 | 2015-05-06 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用 |
CN104045702A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045703B (zh) * | 2013-03-15 | 2021-04-06 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045699A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045700A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045701A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
US20160039876A1 (en) * | 2014-03-28 | 2016-02-11 | Claresa Levetan | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
WO2015158241A1 (en) * | 2014-04-18 | 2015-10-22 | National Institute Of Biological Sciences, Beijing | Reg3 therapeutics |
PL3139948T3 (pl) * | 2014-05-07 | 2020-08-10 | Novo Nordisk A/S | Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
CN105732793A (zh) * | 2014-12-08 | 2016-07-06 | 华东师范大学 | 一种胰再生源蛋白衍生物及其应用 |
CN105727262B (zh) * | 2014-12-08 | 2020-08-25 | 华东师范大学 | 胰再生源蛋白在制备促进过度炎症伤口愈合的药物中的应用 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
WO2017040287A1 (en) | 2015-08-28 | 2017-03-09 | Serpin Pharma, Llc | Methods for treatment of diseases |
EP3426678A4 (en) * | 2016-03-10 | 2020-03-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | CONJUGATES OF ISLAND CELL NEOGENESEPEPTIDES AND ANALOGS AND METHODS THEREFOR |
WO2018205233A1 (zh) | 2017-05-11 | 2018-11-15 | 深圳君圣泰生物技术有限公司 | 多肽化合物在治疗急性胰腺炎中的应用 |
KR101995768B1 (ko) * | 2019-03-13 | 2019-07-03 | (주)엔솔바이오사이언스 | 신규 펩타이드 및 그 용도 |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
CN113993879A (zh) * | 2019-06-13 | 2022-01-28 | 瑞泽恩制药公司 | 在多级色谱过程期间去除非期望的组分的方法 |
BR112022025381A2 (pt) | 2020-06-11 | 2023-01-24 | Provention Bio Inc | Métodos e composições para prevenir diabetes tipo 1 |
CN117442585B (zh) * | 2023-12-25 | 2024-03-19 | 北京爱思益普生物科技股份有限公司 | 一种靶向胰腺癌的雷公藤红素递送体及其制备方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4757060A (en) | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPH01137994A (ja) | 1987-08-10 | 1989-05-30 | Shionogi & Co Ltd | reg蛋白質 |
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
FR2661187B1 (fr) | 1990-04-20 | 1994-08-05 | Inst Nat Sante Rech Med | Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue. |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5261752A (en) * | 1991-09-12 | 1993-11-16 | Nsk Ltd. | Bearing having passive pulser ring |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
HU224160B1 (hu) | 1994-12-21 | 2005-06-28 | Yeda Research And Development Co. Ltd. | P277 Peptidanalógok, ezek alkalmazása a diabétesz in vitro diagnosztizálására szolgáló gyógyszerkészítmények előállítására, gyógyszerkészítmények és diagnosztikus kit |
US5834590A (en) * | 1995-02-22 | 1998-11-10 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
EP0815129B1 (en) | 1995-02-22 | 2011-01-05 | Eastern Virginia Medical School of the Medical College of Hampton Roads | Ingap protein involved in pancreatic islet neogenesis |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DE19735587B4 (de) | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens |
US6311415B1 (en) | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
US6713058B2 (en) | 1999-09-14 | 2004-03-30 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US20040132644A1 (en) * | 2001-10-16 | 2004-07-08 | The Procter & Gamble Company | Composition and method for treating diabetes |
US7166439B2 (en) | 2002-03-01 | 2007-01-23 | Gmp Endotherapeutics, Inc. | Assay for anti-INGAP antibodies |
WO2003094958A1 (en) * | 2002-05-09 | 2003-11-20 | Medtronic Minimed, Inc. | Immunoprotective methods for beta cell neogenesis |
EP1515749B1 (en) | 2002-06-14 | 2012-08-15 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a glp-1 compound |
US6946151B2 (en) | 2002-11-12 | 2005-09-20 | Ayurvedic-Life International, Llc | Therapeutic compositions |
WO2004055519A2 (en) * | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
ES2332590T3 (es) * | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
AU2004224390A1 (en) | 2003-03-19 | 2004-10-07 | Abgenix, Inc. | Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
WO2005035761A1 (en) * | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
JP2007522217A (ja) | 2004-02-10 | 2007-08-09 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ |
CN101128487B (zh) * | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
US8211430B2 (en) | 2005-03-04 | 2012-07-03 | Curedm Group Holdings, Llc | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
EP1883417A2 (en) | 2005-05-25 | 2008-02-06 | Curedm Inc. | Peptides, derivatives and analogs thereof, and methods of using same |
US20090227692A1 (en) | 2005-05-26 | 2009-09-10 | The Johns Hopkins University | Biomarkers for breast cancer |
CN100429227C (zh) * | 2005-06-29 | 2008-10-29 | 常州制药厂有限公司 | Exendin4多肽片段 |
CA2645125A1 (en) * | 2006-03-02 | 2007-09-13 | Oncotherapy Science, Inc. | Methods for diagnosing pancreatic cancer using reg4 protein |
US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
KR20100080519A (ko) | 2007-08-30 | 2010-07-08 | 큐어디엠 인코포레이티드 | 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법 |
US20110082080A1 (en) * | 2007-10-12 | 2011-04-07 | Curedm Group Holdings, Llc | Compositions and methods of using the human proislet peptide receptor |
-
2008
- 2008-08-29 KR KR1020107006933A patent/KR20100080519A/ko not_active Application Discontinuation
- 2008-08-29 MY MYPI2010000893A patent/MY165889A/en unknown
- 2008-08-29 MX MX2013001304A patent/MX337147B/es unknown
- 2008-08-29 NZ NZ599756A patent/NZ599756A/xx not_active IP Right Cessation
- 2008-08-29 CN CN200880114452.5A patent/CN101896499B/zh not_active Expired - Fee Related
- 2008-08-29 EP EP20120183674 patent/EP2559700A3/en not_active Withdrawn
- 2008-08-29 EP EP08798997.6A patent/EP2193142B1/en active Active
- 2008-08-29 NZ NZ583679A patent/NZ583679A/en not_active IP Right Cessation
- 2008-08-29 NZ NZ599755A patent/NZ599755A/xx not_active IP Right Cessation
- 2008-08-29 WO PCT/US2008/074868 patent/WO2009029847A1/en active Application Filing
- 2008-08-29 SG SG2012080883A patent/SG185940A1/en unknown
- 2008-08-29 PT PT87989976T patent/PT2193142E/pt unknown
- 2008-08-29 ES ES08798997.6T patent/ES2534434T3/es active Active
- 2008-08-29 EP EP12183685.2A patent/EP2570431A3/en not_active Withdrawn
- 2008-08-29 DK DK08798997.6T patent/DK2193142T3/da active
- 2008-08-29 SI SI200831410T patent/SI2193142T1/sl unknown
- 2008-08-29 EA EA201000399A patent/EA201000399A1/ru unknown
- 2008-08-29 BR BRPI0815308A patent/BRPI0815308A2/pt not_active IP Right Cessation
- 2008-08-29 US US12/674,573 patent/US8816047B2/en not_active Expired - Fee Related
- 2008-08-29 PL PL08798997T patent/PL2193142T3/pl unknown
- 2008-08-29 MX MX2010002264A patent/MX2010002264A/es active IP Right Grant
- 2008-08-29 JP JP2010523166A patent/JP2010538017A/ja active Pending
- 2008-08-29 AU AU2008292913A patent/AU2008292913B2/en not_active Ceased
- 2008-08-29 CA CA2698100A patent/CA2698100C/en not_active Expired - Fee Related
-
2010
- 2010-02-25 IL IL233024A patent/IL233024A/en not_active IP Right Cessation
- 2010-02-25 IL IL204183A patent/IL204183A/en not_active IP Right Cessation
- 2010-03-12 ZA ZA2010/01798A patent/ZA201001798B/en unknown
- 2010-03-26 MA MA32722A patent/MA31822B1/fr unknown
- 2010-04-05 CO CO10037698A patent/CO6270235A2/es not_active Application Discontinuation
- 2010-12-08 HK HK10111411.6A patent/HK1144823A1/xx not_active IP Right Cessation
-
2013
- 2013-09-10 JP JP2013187508A patent/JP5960661B2/ja not_active Expired - Fee Related
-
2014
- 2014-08-22 US US14/465,835 patent/US20150018272A1/en not_active Abandoned
-
2015
- 2015-03-23 HR HRP20150330TT patent/HRP20150330T1/hr unknown
- 2015-04-07 CY CY20151100332T patent/CY1116169T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150330T1 (hr) | Pripravci i postupci uporabe prostaniäśnog peptida za stanice otoäśiä†a i njegovih analoga | |
JP2001151798A (ja) | 糖尿病治療に有用なglp−1アナログ | |
HRP20170757T1 (hr) | Terapeutski pripravci nukleaze i postupci | |
US20150086548A1 (en) | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions | |
JP2016512213A5 (hr) | ||
Chatenoud et al. | Clinical immunologic interventions for the treatment of type 1 diabetes | |
Musale et al. | Assessment of the potential of temporin peptides from the frog Rana temporaria (Ranidae) as anti‐diabetic agents | |
WO2014004465A1 (en) | Targeted therapeutics | |
IL223895A (en) | Polypeptides and Their Uses as a Remedy for Multiple Sclerosis, Rheumatoid Arthritis, and Other Autoimmune Disorders | |
HU229680B1 (hu) | Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával | |
CA2436139A1 (en) | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies | |
Zahid et al. | Caerulein-and xenopsin-related peptides with insulin-releasing activities from skin secretions of the clawed frogs, Xenopus borealis and Xenopus amieti (Pipidae) | |
WO2011153491A2 (en) | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets | |
US9884091B2 (en) | Treatment of neurological diseases | |
EA035964B1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
KR20190101367A (ko) | 신경 질환의 치료 | |
Rossowski et al. | Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist analogue | |
AR043365A1 (es) | Analogos del glp-1 | |
Abdel-Wahab et al. | A peptide of the phylloseptin family from the skin of the frog Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity | |
WO1996022306A1 (en) | Novel peptide | |
St Georgiev | Immunomodulatory activity of small peptides | |
EP2900691A1 (en) | Generation of new pancreatic beta cells | |
EP4294826A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
Pelidou et al. | Intranasal Administration of Recombinant Mouse Interleukin‐12 Increases Inflammation and Demyelination in Chronic Experimental Autoimmune Neuritis in Lewis Rats | |
JP2012523434A5 (hr) |